Table 4. Association of intact fibroblast growth factor 23 levels with doses of intravenous ferrotherapy over 24 weeks.
| Doses of intravenous ferrotherapy (mg/24 weeks) | |||||||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | ||||||
| Values at baseline | B | SE | p | B | SE | P | |
| Higher i-FGF23 tertile | 66.2 | 20.8 | 0.002 | 60.9 | 20.8 | 0.003 | |
| Hemoglobin (g/dL) | -66.2 | 13.2 | <0.0001 | -63.3 | 12.9 | <0.0001 | |
| TSAT (%) | 0.7 | 1.5 | 0.61 | 0.06 | 1.5 | 0.98 | |
| Log ferritin | -20.0 | 16.7 | 0.23 | -13.5 | 16.1 | 0.40 | |
| Log i-PTH | -5.4 | 15.6 | 0.73 | -11.2 | 15.6 | 0.47 | |
| Log 25-hydroxyvitamin D | 10.3 | 33.6 | 0.75 | 11.2 | 33.2 | 0.73 | |
| Log 1,25-dihydroxyvitamin D | -7.7 | 17.9 | 0.66 | -19.6 | 19.3 | 0.12 | |
| Log hs-CRP | -16.7 | 10.7 | 0.12 | -17.3 | 10.4 | 0.09 | |
| Model 3 | Model 4 | ||||||
| B | SE | P | B | SE | P | ||
| log i-FGF23 | 25.1 | 10.0 | 0.01 | 22.6 | 10.3 | 0.03 | |
| Hemoglobin (g/dL) | -66.8 | 13.2 | <0.0001 | -64.2 | 13.0 | <0.0001 | |
| TSAT (%) | 1.0 | 1.5 | 0.49 | 0.4 | 1.4 | 0.80 | |
| Log ferritin | -24.5 | 16.7 | 0.14 | -18.8 | 15.3 | 0.23 | |
| Log i-PTH | -3.2 | 15.6 | 0.83 | -9.6 | 15.6 | 0.53 | |
| Log 25-hydroxyvitamin D | 9.7 | 33.8 | 0.77 | 9.9 | 33.4 | 0.77 | |
| Log 1,25-dihydroxyvitamin D | -6.8 | 18.0 | 0.70 | -30.0 | 19.4 | 0.12 | |
| Log hs-CRP | -21.0 | 10.5 | 0.04 | -17.4 | 10.4 | 0.09 | |
i-FGF23: intact fibroblast growth factor 23 i-FGF23, TSAT: transferrin saturation, hs-CRP: high sensitive C-reactive protein. Models 1 and 3 were adjusted with age (year), sex (man vs. woman), status of diabetes mellitus (yes vs. no), history of cardiovascular disease (yes vs. no), nutritional state (normal vs. mild to severe malnourished by subjective global assessment), normalized protein catabolic rate (g/kg/day), hemodialysis vintage (months), calcium adjusted for albumin (mg/dL), phosphate (mg/dL). Models 2 and 4 were adjusted with age (year), sex (man vs. woman), status of diabetes mellitus (yes vs. no), hemodialysis vintage (months), calcium adjusted for albumin (mg/dL), phosphate (mg/dL), and treatment of vitamin D and phosphate binder (sevelamer and calcium carbonate).